Heart Attack Risk Up to Sixfold in Rheumatoid Arthritis - eMaxHealth

Heart Attack Risk Up to Sixfold in Rheumatoid Arthritis eMaxHealth If you have rheumatoid arthritis, your risk of experiencing a heart attack (myocardial infarction) is increased by up to sixfold, according to the results ... and more »

Trubion: Pfizer cancels rheumatoid arthritis drug - BusinessWeek

Trubion: Pfizer cancels rheumatoid arthritis drug BusinessWeek Trubion Pharmaceuticals Inc. said Monday that its partner Pfizer Inc. is ending development of one experimental rheumatoid arthritis drug, but will keep ... Trubion slumps after Pfizer kills lead RA drug programFierceBiotech Trubion Provides Update on Clinical Development in RAMarketWatch (press release) Trubion Reveals Pfizer's Decision To Discontinue Development Of Arthritis Drug ...RTT News all 48 news articles »

74-week follow-up of safety of infliximab in patients with refractory ... - 7thSpace Interactive (press release)

74-week follow-up of safety of infliximab in patients with refractory ... 7thSpace Interactive (press release) ... and predictors of adverse events (AEs) in rheumatoid arthritis (RA) patients treated with infliximab and methotrexate in a daily clinical setting. ...

New Data for Investigational Antibody Blocking IL-6 in Rheumatoid Arthritis ... - MarketWatch (press release)

New Data for Investigational Antibody Blocking IL-6 in Rheumatoid Arthritis ... MarketWatch (press release) "BMS-945429/ALD518 is one of the first monoclonal antibodies targeted at the IL-6 cytokine to show clinical activity in patients with rheumatoid arthritis, ... Bristol-Myers says arthritis drug trial met goalReuters BMY Candidate Meets Study GoalZacks.com RA drug safety trial successfulPharmacy Europe all 116 news articles »